Matches in SemOpenAlex for { <https://semopenalex.org/work/W2625238636> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2625238636 endingPage "928" @default.
- W2625238636 startingPage "919" @default.
- W2625238636 abstract "To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice.TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion.322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS28 <2.6; 38.05%) were 216 out of 226 patients with available DAS28 (p<0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%).This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care." @default.
- W2625238636 created "2017-06-23" @default.
- W2625238636 creator A5006913066 @default.
- W2625238636 creator A5018149318 @default.
- W2625238636 creator A5026614224 @default.
- W2625238636 creator A5037295594 @default.
- W2625238636 creator A5051535034 @default.
- W2625238636 creator A5051900744 @default.
- W2625238636 creator A5053288231 @default.
- W2625238636 creator A5057958762 @default.
- W2625238636 creator A5058470561 @default.
- W2625238636 creator A5066368809 @default.
- W2625238636 creator A5068168029 @default.
- W2625238636 creator A5084430360 @default.
- W2625238636 creator A5084838808 @default.
- W2625238636 creator A5088324181 @default.
- W2625238636 date "2017-05-19" @default.
- W2625238636 modified "2023-10-14" @default.
- W2625238636 title "Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study." @default.
- W2625238636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28516890" @default.
- W2625238636 hasPublicationYear "2017" @default.
- W2625238636 type Work @default.
- W2625238636 sameAs 2625238636 @default.
- W2625238636 citedByCount "0" @default.
- W2625238636 crossrefType "journal-article" @default.
- W2625238636 hasAuthorship W2625238636A5006913066 @default.
- W2625238636 hasAuthorship W2625238636A5018149318 @default.
- W2625238636 hasAuthorship W2625238636A5026614224 @default.
- W2625238636 hasAuthorship W2625238636A5037295594 @default.
- W2625238636 hasAuthorship W2625238636A5051535034 @default.
- W2625238636 hasAuthorship W2625238636A5051900744 @default.
- W2625238636 hasAuthorship W2625238636A5053288231 @default.
- W2625238636 hasAuthorship W2625238636A5057958762 @default.
- W2625238636 hasAuthorship W2625238636A5058470561 @default.
- W2625238636 hasAuthorship W2625238636A5066368809 @default.
- W2625238636 hasAuthorship W2625238636A5068168029 @default.
- W2625238636 hasAuthorship W2625238636A5084430360 @default.
- W2625238636 hasAuthorship W2625238636A5084838808 @default.
- W2625238636 hasAuthorship W2625238636A5088324181 @default.
- W2625238636 hasConcept C126322002 @default.
- W2625238636 hasConcept C197934379 @default.
- W2625238636 hasConcept C198451711 @default.
- W2625238636 hasConcept C23131810 @default.
- W2625238636 hasConcept C2777178219 @default.
- W2625238636 hasConcept C2777575956 @default.
- W2625238636 hasConcept C71924100 @default.
- W2625238636 hasConcept C72563966 @default.
- W2625238636 hasConceptScore W2625238636C126322002 @default.
- W2625238636 hasConceptScore W2625238636C197934379 @default.
- W2625238636 hasConceptScore W2625238636C198451711 @default.
- W2625238636 hasConceptScore W2625238636C23131810 @default.
- W2625238636 hasConceptScore W2625238636C2777178219 @default.
- W2625238636 hasConceptScore W2625238636C2777575956 @default.
- W2625238636 hasConceptScore W2625238636C71924100 @default.
- W2625238636 hasConceptScore W2625238636C72563966 @default.
- W2625238636 hasIssue "6" @default.
- W2625238636 hasLocation W26252386361 @default.
- W2625238636 hasOpenAccess W2625238636 @default.
- W2625238636 hasPrimaryLocation W26252386361 @default.
- W2625238636 hasRelatedWork W2066258204 @default.
- W2625238636 hasRelatedWork W2114448779 @default.
- W2625238636 hasRelatedWork W2736593664 @default.
- W2625238636 hasRelatedWork W2891874823 @default.
- W2625238636 hasRelatedWork W2898156360 @default.
- W2625238636 hasRelatedWork W2996380604 @default.
- W2625238636 hasRelatedWork W3087945819 @default.
- W2625238636 hasRelatedWork W3150509816 @default.
- W2625238636 hasRelatedWork W4206878291 @default.
- W2625238636 hasRelatedWork W4239841759 @default.
- W2625238636 hasVolume "35" @default.
- W2625238636 isParatext "false" @default.
- W2625238636 isRetracted "false" @default.
- W2625238636 magId "2625238636" @default.
- W2625238636 workType "article" @default.